{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"1.2","value":"1.1"},{"groupId":"OG001","lowerLimit":"1.1","upperLimit":"1.4","value":"1.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"description":"Time to 50% reduction in absolute lymphocyte count (ALC) was defined as the number of days (hours if applicable) from the date of first dose to the date when the ALC had reduced to 50% of the baseline value. Only participants with a baseline of ALC \\> 5 × 10\\^9 /L were included in the analysis. For participants who never achieved a 50% reduction in ALC, the participant's data were not included in the analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 79 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG000","title":"Main Cohort"},{"description":"Participants in the Main Cohort received ABT-199 tablets once daily (QD) orally for up to 79 months,and those in the Safety Expansion Cohort received ABT-199 tablets once daily (QD) orally for up to 68 months. For both groups, the starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG001","title":"All Treated Participants"}],"paramType":"MEAN","populationDescription":"All treated participants with a baseline of ALC \\> 5 × 10\\^9 /L, a 50% reduction in ALC, and available data","reportingStatus":"POSTED","timeFrame":"Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up","title":"Time to 50% Reduction in Absolute Lymphocyte Count","type":"SECONDARY","unitOfMeasure":"weeks"}